Author correction: Bifidobacterium animalis subsp. lactis BLa80 for preventing allergic, respiratory, and gastrointestinal diseases in young children in China: a randomized double-blind placebo-controlled trial
Article information
Clinical and Experimental Pediatrics 2026;69(2):150-162.
Published online: October 30, 2025
https://doi.org/10.3345/cep.2025.01256
To the editor,
Upon careful re-examination of the published article, we identified two inadvertent errors in the Results section of the Abstract. The original text incorrectly stated the direction of change for antimicrobial peptide levels between the intervention group (IG) and control group (CG).
We sincerely apologize for this editorial oversight. This correction does not alter the primary conclusions of the study regarding the efficacy of Bifidobacterium animalis subsp. lactis BLa80 in preventing allergic, respiratory, and gastrointestinal diseases in young children.
The two errors should be corrected as follows:
1. First correction
Original (incorrect): "Postintervention, the IG had significantly lower concentrations of LL-37 ..."
Corrected: "Postintervention, the IG had significantly higher concentrations of LL-37..."
2. Second correction
Original (incorrect): “Probiotic supplementation was also associated with a lower risk of URTIs (IG vs. CG: 40.3% vs. 20.7%; risk ratio [RR], 0.752; 95% confidence interval [CI], 0.653–0.866)…”
Corrected: “Probiotic supplementation was also associated with a lower risk of URTIs (CG vs. IG: 40.3% vs. 20.7%; risk ratio [RR], 0.752; 95% confidence interval [CI], 0.653–0.866)...”